

Full chemo doses may improve survival in breast cancer

11 September 2019

being reduced



(HealthDay)—Maintaining full doses of chemotherapy, especially early in the treatment course, is important for survival of intermediate or high-risk breast cancer patients, according to a study published in the August issue of the *Journal of the National Comprehensive Cancer Network*.

Zachary Veitch, M.D., from the University of Calgary in Canada, and colleagues evaluated the impact of [chemotherapy](#) total cumulative dose (TCD), and early (5-fluorouracil/epirubicin/cyclophosphamide) versus late (docetaxel only) dose reductions, on [survival outcomes](#) among women with stage I to III, hormone receptor-positive/negative, human epidermal growth factor receptor 2 -negative breast [cancer](#) treated with adjuvant 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel chemotherapy (from 2007 through 2014).

The researchers noted that 1,302 patients were evaluated for dose reductions, with 16 percent

APA citation: Full chemo doses may improve survival in breast cancer (2019, September 11) retrieved 15 October 2019 from <https://medicalxpress.com/news/2019-09-full-chemo-doses-survival-breast.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.